ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access for ACE-011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03724227
Expanded Access Status : Available
First Posted : October 30, 2018
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

Condition or disease Intervention/treatment
Myelodysplastic Syndrome Drug: ACE-011

Study Type : Expanded Access
Expanded Access Type : Individual Patients
Official Title: Expanded Access for ACE-011



Intervention Details:
  • Drug: ACE-011
    ACE-011 will be administered subcutaneous injection
    Other Name: Sotatercept

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03724227


Contacts
Contact: Celgene Medical Information 1-888-771-0141 medinfo@celgene.com

Locations
United States, New Jersey
Celgene
Summit, New Jersey, United States, 07901
Sponsors and Collaborators
Celgene

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03724227     History of Changes
Other Study ID Numbers: ACE-011
First Posted: October 30, 2018    Key Record Dates
Last Update Posted: October 30, 2018
Last Verified: October 2018

Keywords provided by Celgene:
Expanded Access
Compassionate Use

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms